Is olaparib the only PARP inhibitor that has been approved?
- 1 people answered
Edit Tags
Tags are used to find the best answers
You might also be interested in
Some of the Famous Cancer Hospitals in Bangalore Includes: Fortis Hospital, Cunningham Road Fortis Hospital, Bannerghatta Road Columbia Asia Referral Hospital, Yeshwanthpur Mazumdar Shaw Medical Centre, Bommasandra, Health City HCG Cancer Centre, Koramangala Columbia Asia Hospital, W....
Dear All, Myelofibrosis & osteopetrosis are two different diseases, According to your symptoms, it points towards Myelofibrosis. It is a rare form of cancer. Please get in touch with our Medical Assistant to evaluate your condition. There are many medical management techniques. Patients b....
Yes it is. Women who consume even a few drinks a week possess an increased risk for breast cancer. Scientists still haven’t yet found out exactly why this happens. Alcohol may raise estrogen levels, an important factor in the development of breast cancer. One characteristic of a cancer cell is that ....
Credihealth is not a medical practitioner and does not provide medical advice. You should consult your doctor or with a healthcare professional before starting any diet, exercise, supplementation or medication program. Know More
Reviewed by:Dr. Nitika Sharma - BDS
Reviewed by:Dr. Rakesh Kumar - MBBS, MS
Rahul Sharma
Yes, PARP inhibitors are relatively newer class of drugs and scientists have just begun to explore their functionality and usage in Cancer treatment. LYNPARZA is the first and only PARP inhibitor approved in 2 distinct settings: For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. For the treatment of adult patients with suspected deleterious germline BRCA-mutated advanced ovarian cancer which has been treated with 3 or more prior lines of chemotherapy. Patients should be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Poly (ADP-ribose) Polymerase, or PARP, enzymes mediate DNA repair by transferring ADP-ribose units to preexisting ADP-ribose chains on proteins and to proteins. This ADP–ribosylation process recruits DNA repair enzymes, thereby maintaining genomic integrity. Inhibiting this process can lead to the accumulation of DNA damage and, ultimately, cell death.